Strain Name |
CB17/lcr-PrkdcscidNcr1tm1(NCR1)Bcgen/Bcgen
|
Common Name | B-hNKP46 mice(CB-17 SCID) |
Background | CB-17 SCID | Catalog number | 112259 |
Aliases | CD335, LY94, NK-p46, NKP46 |
Protein expression of NKP46 in spleen
In vivo efficacy of anti-human NKP46-based Ab in B-hNKP46 mice(CB-17 SCID)
In vivo efficacy of anti-human NKP46-based Ab in B-hNKP46 mice(CB-17 SCID)
Antitumor activity of anti-human NKP46-based Ab in B-hNKP46 mice(CB-17 SCID). (A) Anti-human NKP46-based Ab inhibited BxPC-3 tumor growth in B-hNKP46 mice(CB-17 SCID). BxPC-3 cells (5E6) were subcutaneously implanted into B-hNKP46 mice(CB-17 SCID) (male, 7-8 week-old, n=6). Mice were grouped when tumor volume reached approximately 100-150 mm3, at which time they were treated with anti-human NKP46-based Ab with doses and schedules indicated in panel A. (B) Body weight changes during treatment. As shown in panel A, anti-human NKP46-based Ab was efficacious in controlling tumor growth in B-hNKP46 mice(CB-17 SCID). Values are expressed as mean ± SEM. (All antibodies were provided by the clients)